FreeIn Brief ASCO names advance of the year: progress in treating rare cancers February 01, 2019Vol.45 No.05
Free Industry a no-show as Sens. Grassley and Wyden hold hearing on drug pricing February 01, 2019Vol.45 No.05By Claire Dietz
Free Gottlieb: FDA to expand real-world data infrastructure to enhance AI capabilities February 01, 2019Vol.45 No.05By Matthew Bin Han Ong
FreeGuest Editorial The Prostate Cancer Prevention Trial and nine lessons in prostate cancer medicine February 01, 2019Vol.45 No.05By Otis W. Brawley
FreeGuest Editorial 20-year follow-up data are in: Prostate cancer prevention works; concerns about high-grade disease dismissed February 01, 2019Vol.45 No.05By Ian Thompson Jr., Phyllis Goodman and Catherine Tangen
Drugs & TargetsFree European Commission authorizes Rubraca tablets in ovarian cancer January 25, 2019Vol.45 No.04
Drugs & TargetsFree Bristol-Myers Squibb withdraws U.S. application for Opdivo + Yervoy in first-line lung cancer January 25, 2019Vol.45 No.04
Drugs & TargetsFree FDA finalizes policy on labeling for accelerated approval drugs January 25, 2019Vol.45 No.04
Drugs & TargetsFree FDA grants Illumina’s TruSight Assay Breakthrough Device designation January 25, 2019Vol.45 No.04
